Search results
Desjardins Analysts Cut Earnings Estimates for Dollarama Inc. (TSE:DOL)
ETF DAILY NEWS· 17 hours agoDesjardins analyst C. Li now expects that the company will earn $0.75 per share for the quarter, down from their previous forecast of $0.78. Desjardins currently has a “Buy” rating and a $133.00 ...
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside - Regenxbio...
Benzinga· 6 days agoGoldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Barbara Corcoran’s Favorite Things — And Where to Get Them Cheaply
GoBankingRates via AOL· 6 days agoMarketers have been using celebrity recommendations to make advertisements believable and to...
The Baldwin Insurance Group, Inc. (NASDAQ:BRP) Receives $34.00 Average PT from Brokerages
ETF DAILY NEWS· 3 days agoThe Baldwin Insurance Group, Inc. (NASDAQ:BRP – Get Free Report) has been assigned an average...
Ongoing Efforts to Expand Kidney Donor Pool Seem Mostly Safe
Medscape· 2 days agoLiving donors had a similar risk for hypertension and albuminuria after donation as nondonors, and...
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Zacks· 7 days agoFree Report) . Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important ...
'I didn’t think it was going to work': 5 beauty hacks that TikTok goes wild for
The Daily Dot· 1 day agoIn recent years, social media influencers have revolutionized the beauty industry by altering how...
AssetMark COO Hansen sells shares worth over $365k By Investing.com
Investing.com· 2 days agoHansen, sold company shares in a transaction on June 10, 2024. The transaction involved a total of...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days agoOSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform